Repurposing of Rutan showed effective treatment for COVID-19 disease

• Published in: Frontiers in medicine Vol. 10; p. 1310129
• Main Authors: Salikhov, Shavkat I, Abdurakhmonov, Ibrokhim Y, Oshchepkova, Yuliya I, Ziyavitdinov, Jamolitdin F, Berdiev, Nodir Sh, Aisa, Haji Akber, Shen, Jingshan, Xu, Yechun, Xu, H Eric, Jiang, Xiangrui, Zhang, Leike, Vypova, Natalia L, Allaberganov, Dilshod Sh, Tagayalieva, Nigora A, Musabaev, Erkin I, Ibadova, Gulnara A, Rajabov, Ilxom B, Lokteva, Lyubov M
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.11.2023
• Subjects: 3CLpro; COVID-19; Medicine; RdRp; Rhus coriaria; Rutan; SARS-CoV-2; COVID-19; clinical trial; Rhus coriaria; SARS-CoV-2; Rutan; RdRp; 3CLpro
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2023.1310129

Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children. ClinicalTrials.gov, ID NCT05862883.